Fusion Antibodies (FAB) Competitors GBX 13.38 -1.63 (-10.83%) As of 10:34 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock FAB vs. ORPH, IMM, REDX, ETX, HEMO, HVO, SBTX, SAR, AREC, and COSShould you be buying Fusion Antibodies stock or one of its competitors? The main competitors of Fusion Antibodies include Open Orphan (ORPH), ImmuPharma (IMM), Redx Pharma (REDX), e-therapeutics (ETX), Hemogenyx Pharmaceuticals (HEMO), hVIVO (HVO), SkinBioTherapeutics (SBTX), Sareum (SAR), Arecor Therapeutics (AREC), and Collagen Solutions plc (COS.L) (COS). These companies are all part of the "biotechnology" industry. Fusion Antibodies vs. Its Competitors Open Orphan ImmuPharma Redx Pharma e-therapeutics Hemogenyx Pharmaceuticals hVIVO SkinBioTherapeutics Sareum Arecor Therapeutics Collagen Solutions plc (COS.L) Open Orphan (LON:ORPH) and Fusion Antibodies (LON:FAB) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, media sentiment, dividends, institutional ownership, analyst recommendations, valuation, earnings and risk. Do insiders & institutionals have more ownership in ORPH or FAB? 13.2% of Fusion Antibodies shares are owned by institutional investors. 6.2% of Fusion Antibodies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Which has better earnings & valuation, ORPH or FAB? Open Orphan has higher revenue and earnings than Fusion Antibodies. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOpen Orphan£34.71M0.00N/AN/AN/AFusion Antibodies£1.97M7.74-£4.10M-£0.02-743.06 Does the media favor ORPH or FAB? In the previous week, Fusion Antibodies had 1 more articles in the media than Open Orphan. MarketBeat recorded 1 mentions for Fusion Antibodies and 0 mentions for Open Orphan. Open Orphan's average media sentiment score of 0.00 equaled Fusion Antibodies'average media sentiment score. Company Overall Sentiment Open Orphan Neutral Fusion Antibodies Neutral Is ORPH or FAB more profitable? Open Orphan has a net margin of 0.00% compared to Fusion Antibodies' net margin of -195.95%. Open Orphan's return on equity of 0.00% beat Fusion Antibodies' return on equity.Company Net Margins Return on Equity Return on Assets Open OrphanN/A N/A N/A Fusion Antibodies -195.95%-137.11%-63.78% SummaryOpen Orphan beats Fusion Antibodies on 5 of the 8 factors compared between the two stocks. Get Fusion Antibodies News Delivered to You Automatically Sign up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FAB vs. The Competition Export to ExcelMetricFusion AntibodiesBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£15.20M£232.12M£6.13B£2.62BDividend YieldN/A3.80%5.69%5.28%P/E Ratio-743.0695.4585.864,447.62Price / Sales7.746,202.84540.53100,394.18Price / Cash9.0213.1937.9227.90Price / Book3.81113.2812.988.87Net Income-£4.10M-£90.99M£3.30B£5.89B7 Day Performance-22.55%3.91%4.73%0.70%1 Month Performance-16.35%6.76%9.96%5.81%1 Year Performance207.54%725.51%84.61%155.75% Fusion Antibodies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FABFusion AntibodiesN/AGBX 13.38-10.8%N/A+251.3%£15.20M£1.97M-743.0648News CoverageORPHOpen OrphanN/AN/AN/AN/A£67.09M£34.71M-25.30179IMMImmuPharmaN/AGBX 11.90-5.2%N/A+519.9%£59.47MN/A-1,337.0813REDXRedx PharmaN/AN/AN/AN/A£58.35M£4.20M-150.00101Positive NewsGap UpHigh Trading VolumeETXe-therapeuticsN/AN/AN/AN/A£52.59M£295K-450.0035High Trading VolumeHEMOHemogenyx PharmaceuticalsN/AGBX 1,080-0.2%N/A+94,900.0%£51.05MN/A-596.3614Gap DownHVOhVIVO1.6181 of 5 starsGBX 7.30-6.4%GBX 23+215.1%-75.2%£50.17M£51.28M470.97N/AGap DownSBTXSkinBioTherapeuticsN/AGBX 14.88-0.8%N/A+34.1%£38.49M£2.68M-1,190.0011SARSareumN/AGBX 25.10-3.5%N/A-28.6%£34.44MN/A-965.383,211Gap DownARECArecor TherapeuticsN/AGBX 83.75-3.2%N/A+11.9%£31.62M£5.05M-270.1610COSCollagen Solutions plc (COS.L)N/AN/AN/AN/A£30.99M£4.01M-8.283,350 Related Companies and Tools Related Companies Open Orphan Alternatives ImmuPharma Alternatives Redx Pharma Alternatives e-therapeutics Alternatives Hemogenyx Pharmaceuticals Alternatives hVIVO Alternatives SkinBioTherapeutics Alternatives Sareum Alternatives Arecor Therapeutics Alternatives Collagen Solutions plc (COS.L) Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:FAB) was last updated on 10/9/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredBuilding The Infrastructure for the Coming Financial ResetWhile China pushes nearly $1 trillion through its new digital currency, one emerging company is quietly buildi...Intellistake | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredA Huge Shift Is Underway in AmericaWall Street legend issues chilling new warning: "I've never seen anything as dangerous as this" The man who...Stansberry Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Fusion Antibodies plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Fusion Antibodies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
